This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.
Original paper

Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia

Volume: 102, Issue: 4, Pages: e132 - e135
Published: Jan 12, 2017
Abstract
Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia *Includes one patient who completed the study in remission, with RFS of 59.7 months (4.97 years).**One patient was censored after 43 days (1.4 months) because of withdrawal of consent.***Patients could have both rearrangements and translocations.HSCT: hematopoietic stem cell...
Paper Details
Title
Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia
Published Date
Jan 12, 2017
Volume
102
Issue
4
Pages
e132 - e135
© 2025 Pluto Labs All rights reserved.
Step 1. Scroll down for details & analytics related to the paper.
Discover a range of citation analytics, paper references, a list of cited papers, and more.